Literature DB >> 8214260

Nodular regenerative hyperplasia in partial hepatectomy specimens.

K Washington1, K L Lane, W C Meyers.   

Abstract

To investigate possible associations of nodular regenerative hyperplasia (NRH) with antitumor chemotherapy, we reviewed 72 partial hepatic resections (55 with metastatic tumor, 12 hepatocellular carcinomas, and five benign neoplasms). Thirty autopsy livers from adults without malignancies served as controls. Studies included hematoxylin and eosin, reticulin, and trichrome stains and immunostaining for proliferating cell nuclear antigen (PCNA). Five of 72 livers (7%) had NRH. All five patients had received chemotherapy, one by intrahepatic artery infusion. Four had received chemotherapy 2 months or less before undergoing partial hepatectomy. These five cases represented 15% of the 33 patients who received chemotherapy. No NRH was seen in autopsy control livers. In contrast to NRH, multiple hyperplastic foci were seen in 28 of 72 livers (39%). This finding did not correlate with chemotherapy. Two of 30 control livers (7%) showed similar mild regenerative changes. In only one case of NRH was PCNA staining increased over controls. A band of PCNA-positive hepatocytes was seen adjacent to the tumor in 21 cases, suggesting that the presence of tumor may cause a local increase in PCNA expression. Mitoses in hepatocytes and assessment of the thickness of liver cell plates were more sensitive indicators of regeneration than PCNA. Vascular changes, such as sinusoidal fibrosis (11 of 72 cases), thickened hepatic arterioles (13 of 72 cases), and mild thickening of central veins (10 of 72 cases), did not correlate with NRH, hyperplastic foci, or chemotherapy. No cases of hepatoportal sclerosis were identified.

Entities:  

Mesh:

Year:  1993        PMID: 8214260     DOI: 10.1097/00000478-199311000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats.

Authors:  Meihong Deng; Hai Huang; Hao Jin; Olaf Dirsch; Uta Dahmen
Journal:  Invest New Drugs       Date:  2010-02-12       Impact factor: 3.850

Review 2.  Evolution in the treatment of metastatic colorectal carcinoma of the liver.

Authors:  Charlotte-E Ariyan; Ronald-R Salem
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

3.  Nodular regenerative hyperplasia secondary to neoadjuvant chemotherapy for colorectal liver metastases.

Authors:  Maartje A J van den Broek; Steven W M Olde Damink; Ann Driessen; Cornelis H C Dejong; Marc H A Bemelmans
Journal:  Case Rep Med       Date:  2009-11-22

4.  Pseudocirrhosis in a pancreatic cancer patient with liver metastases: a case report of complete resolution of pseudocirrhosis with an early recognition and management.

Authors:  Soonmo Peter Kang; Tamar Taddei; Bruce McLennan; Jill Lacy
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

Review 5.  Treatment for colorectal liver metastases: a review.

Authors:  Hiroshi Shimada; Kuniya Tanaka; Itaru Endou; Yasushi Ichikawa
Journal:  Langenbecks Arch Surg       Date:  2009-07-07       Impact factor: 3.445

6.  Cirrhosis-like radiological pattern in patients with breast cancer.

Authors:  César Gómez Raposo; Andrés Redondo Sánchez; Félix Guerra-Gutiérrez; Beatriz Castelo Fernández; Silvia Gómez Senent; Enrique Espinosa Arranz; Beatriz Martínez Martínez; Pilar Zamora Auñón; Manuel González Barón
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

7.  Nodular regenerative hyperplasia and portal hypertension in a patient with coeliac disease.

Authors:  Erwin Biecker; Hans-Peter Fischer; Michael Schepke
Journal:  Case Rep Gastrointest Med       Date:  2011-08-28

8.  Chemotherapy-induced liver injury in metastatic colorectal cancer: about 48 cases.

Authors:  Faten Limaiem; Saadia Bouraoui
Journal:  Pan Afr Med J       Date:  2018-07-05

9.  Partial splenic embolization to permit continuation of systemic chemotherapy.

Authors:  Jose Hugo M Luz; Paula M Luz; Edson Marchiori; Leonardo A Rodrigues; Hugo R Gouveia; Henrique S Martin; Igor M Faria; Roberto R Souza; Roberto de Almeida Gil; Alexandre de M Palladino; Karina B Pimenta; Henrique S de Souza
Journal:  Cancer Med       Date:  2016-09-09       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.